Design, Synthesis, and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Siqi Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Androgen deprivation in cases of castration-resistant prostate cancer (CRPC) leads to adverse effects, including loss of muscle and bone mass and gain of subcutaneous fat. The tumor-specific suppression of androgen receptor (AR) signaling, while not global, may reduce side effects. We present a class of small-molecular conjugates consisting of an AR antagonist linked to a heat shock protein 90 (Hsp90) inhibitor. We demonstrate that the high accumulation of Hsp90 on the surface of CRPC cells allows uptake of conjugates and increases the enrichment of drugs in the tumor cells. After penetrating prostate cancer cells, the conjugates not only inhibit AR function by the antagonist component but also bind to Hsp90 and suppress the AR protein level. Compared to AR antagonists, these conjugates showed improved tumor-targeting ability and enhanced potency against Enzalutamide-resistant 22Rv1 cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
- Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
- Laboratory for Marine Drugs and Bioproducts, Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong 266137, China.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Zhang, S., Meng, X., Zhang, S., Li, B., Jin, W., Zhang, C., Liu, Z., Hu, X., Ge, L., Yu, Z., Li, Z., Ma, S., Wang, X., Li, L., & Qin, C. (2023). Design, Synthesis, and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01970
Vancouver
Zhang S, Meng X, Zhang S, Li B, Jin W, Zhang C, et al. Design, Synthesis, and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01970
BibTeX
@article{Zhang2023,
author = {Zhang, Siqi and Meng, Xiaolei and Zhang, Sai and Li, Baohu and Jin, Wencong and Zhang, Chengwei and Liu, Zhaojuan and Hu, Xiaolin and Ge, Ling and Yu, Zhonghao and Li, Zhuoyue and Ma, Shumin and Wang, Xiao and Li, Liming and Qin, Chong},
title = {Design, Synthesis, and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01970}
}
EUVIMED